Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

228
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
228
Censoring Survival Data01:09

Censoring Survival Data

152
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
152
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

160
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
160
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

197
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
197
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

492
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
492
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

301
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
301

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining tertiary lymphoid structures and tumor stroma percentage for predicting prognosis and chemotherapy benefits in stage II-III colorectal cancer.

BMC cancer·2026
Same author

Tumor ecosystem subtyping of breast cancer based on somatic mutations and network propagation reveals distinct prognostic and genomic landscapes.

Frontiers in genetics·2026
Same author

Monitoring in vivo transcription with synthetic serum markers.

Nature communications·2026
Same author

Development of nucleic acid testing technology for quarantine pest <i>Globodera rostochiensis</i> based on a species-specific DNA fragment.

PeerJ·2026
Same author

Multi-parameter controlled acoustofluidic assembly of colloidal and cellular structures.

Colloids and surfaces. B, Biointerfaces·2026
Same author

Aptamer-mediated portable SERS sensor based on bimetallic magnetic nanotubes for internal standard-calibrated detection of multi-target disease markers.

Biosensors & bioelectronics·2026

Related Experiment Video

Updated: Jul 27, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K

More efficient and inclusive time-to-event trials with covariate adjustment: a simulation study.

Raphaëlle Momal1, Honghao Li1, Paul Trichelair1

  • 1Owkin Inc, New York, USA.

Trials
|June 6, 2023
PubMed
Summary

Adjusting for prognostic factors in time-to-event clinical trials significantly reduces sample size needs, especially with high event rates. This covariate adjustment enhances trial efficiency and inclusivity, particularly for advanced cancers.

Keywords:
Covariate adjustmentCox regressionEligibility criteriaTrial design

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K

Related Experiment Videos

Last Updated: Jul 27, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K

Area of Science:

  • Clinical Trial Design
  • Biostatistics
  • Survival Analysis

Background:

  • Covariate adjustment is known to increase statistical power in randomized trials with continuous outcomes.
  • Factors influencing power gains from covariate adjustment in time-to-event trials are less understood.
  • Broadening eligibility criteria often decreases statistical power in clinical trials.

Purpose of the Study:

  • To investigate factors influencing statistical power and sample size requirements in time-to-event clinical trials.
  • To quantify the sample size reduction achievable through covariate adjustment.
  • To assess the impact of covariate adjustment on maintaining power when broadening eligibility criteria.

Main Methods:

  • Parametric simulations were employed to model time-to-event outcomes.
  • Simulations utilized data from the Cancer Genome Atlas (TCGA) hepatocellular carcinoma (HCC) cohort.
  • The prognostic performance of covariates (C-index) and cumulative incidence were key simulation parameters.

Main Results:

  • Sample size reduction from covariate adjustment increases with the covariate's prognostic performance (C-index) and the event's cumulative incidence.
  • For a covariate with C-index=0.65, sample size reduction ranged from 3.1% (10% cumulative incidence) to 29.1% (90% cumulative incidence).
  • Covariate adjustment maintained statistical power when broadening eligibility criteria, reducing screened patients by 2.4-fold in an HCC adjuvant trial simulation.

Conclusions:

  • Systematic adjustment for prognostic covariates enhances the efficiency and inclusivity of clinical trials, particularly those with high cumulative incidence.
  • Covariate adjustment is crucial for maintaining statistical power in trials with broad eligibility criteria, common in advanced cancer studies.
  • The Cox-Snell R-squared provides a conservative estimate of sample size reduction benefits from covariate adjustment.